41036-01-5

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-(2-hydroxyethyl)morpholin-3-one is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to form stable and bioactive compounds.
Used in Polymer and Resin Production:
HEMO is used as a building block in the production of polymers and resins, contributing to the development of materials with specific properties and applications.
Used in Industrial Processes:
4-(2-hydroxyethyl)morpholin-3-one is used as a corrosion inhibitor and chelating agent in various industrial processes, enhancing the efficiency and longevity of equipment and machinery.
Used in Coatings, Adhesives, and Sealants:
HEMO is used in the formulation of coatings, adhesives, and sealants, providing improved performance and durability to these products.

InChI:InChI=1/C6H11NO3/c8-3-1-7-2-4-10-5-6(7)9/h8H,1-5H2

Upstream product

• 622-40-2 2-(morpholin-4-yl)ethanol 
• 96-34-4 methyl chloroacetate 
• 111-42-2 2,2'-iminobis[ethanol] 
• 186294-80-4 Chloro-acetic acid 2-[(2-chloro-acetyl)-(2-hydroxy-ethyl)-amino]-ethyl ester 
• 186294-83-7 2-(3-oxomorpholino)ethyl chloroacetate 
• 892871-54-4 4-(2-(benzyloxy)ethyl)morpholin-3-one 

Downstream Products

• 205193-97-1 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(2-(3-oxomorpholino)ethoxy)quinazoline hydrochloride 
• 205193-82-4 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(3-oxomorpholino)ethoxy)quinazoline hydrochloride 
• 79874-76-3 3-(4-propyl-heptyl)-4-(2-hydroxyethyl)-morpholine 
• 98092-92-3 rac-4-(2-hydroxyethyl)-3-(4-propylheptyl) morpholine hydrochloride 

Relevant academic research and scientific papers

MODULATORS OF G-PROTEIN COUPLED RECEPTORS

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor ("GLP?1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is benficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancment of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) -arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

Selective, Catalytic, and Dual C(sp3)-H Oxidation of Piperazines and Morpholines under Transition-Metal-Free Conditions

By using cheap and innocuous reagents, such as NaClO2, NaOCl, and catalytic amounts of TEMPO, a new environmentally friendly protocol for the selective and catalytic TEMPO C(sp3)-H oxidation of piperazines and morpholines to 2,3-diketopiperazines (2,3-DKP) and 3-morpholinones (3-MPs), respectively, has been developed. This novel direct access to 2,3-DKP from piperazines provides significant advantages over the traditional N-monoacylation/intramolecular C-N cyclization procedure. Additionally, by modulating the amounts of TEMPO, 2-alkoxyamino-3-morpholinone can be prepared from morpholine derivatives, which would enable further functionalization at the C2 position of the morpholine skeleton.

METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS

The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl and alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propylheptyl)morpholino)ethan-1-ol with the INN name delmopinol. The invention also relates to 1-chloro-4-propylhept-3-ene, 1-iodo-4-propylhept-3-ene, 8a-(4-5 propylheptyl)hexahydrooxazolo[2,3-c][1,4]oxazine, 8a-(4-propylhept-3-en-1-yl)hexahydrooxazolo[2,3-c][1,4]oxazine and 2-(3-(4-propylhept-3-en-1-yl)morpholino)ethan-1-ol which are intermediates in the delmopinol process.

PROCESS FOR THE PREPARATION OF DELMOPINOL AND DERIVATIVES THEREOF

A process for the preparation of delmopinol (3-(4-propylheptyl)-4-morpholinethanol) or a derivative or a pharmaceutically acceptable salt, or a solvate thereof, including an hydrate, comprises reacting oxazolidin [2, 3-c] morpholine and a grignard reagent, and optionally converting the delmopinol (or derivative) free base into a pharmaceutically acceptable salt. The oxazolidin [2, 3-c] morpholine and the grignard reagent are useful as intermediates in the production process.

THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R1, q, p, R2, t, Ar1, L1, R3 and R4 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

The structure of a human metabolite of pholcodine

The structure of a metabolite of pholcodine produced by humans is shown, by spectroscopic and synthetic data, to be a morpholin-3-one (amide) derivative rather than the alternative morpholin-2-one (lactone) isomer. Acylation of diethanolamine leads to an